Equibles does not estimate personal net worth.
Get an email with a short summary when Gilead Sciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get GILD alertsDaniel O'Day is recorded as CEO at Gilead Sciences, Inc. (GILD). Daniel O'Day has spoken on 25 earnings calls and 4 other investor events across 1 company, most recently for Gilead Sciences, Inc. on September 9, 2026. Gilead Sciences, Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Gilead Sciences, Inc. includes Daniel P. O’Day (CEO), Robin L. Washington (CFO), Diane E. Wilfong (Chief Accounting Officer) and 7 others.
“Oh, I think we're at this point where we really also need to execute and deliver, right? 2026 was a year we really focused on shaping the portfolio, bringing new molecules, both internal and external, into the fold.”
“As you'll see from today's results, Gilead has delivered another quarter of commercial excellence with based business sales up 10% year-over-year, our strongest second-quarter growth in three years, driven by our HIV portfolio, Tredelvi and Livedelzi.”
“But first of all, thanks for having us here. And we've been talking at this conference for a while now. I would say this is a really important time for Gilead. It's really just watching our strategy play out over the past seven years.”
“Well, Courtney, thank you for having me. I'm delighted to have this chance to chat with you as well and to be with all of you. I think the key message for Gilead right now is that we're really in a position of strength.”
“I'm pleased to share highlights from Gilead's first quarter, which has extended our consistent track record of commercial, clinical, and financial execution.”
Drug Manufacturers - General · Healthcare
CEO
